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Highlights 
 
Hospital and community pharmacists have an important role in supporting patients’ 
medicines use after discharge from hospital. However little research has studied how this 
resource might be targeted. 
 
In this study, patients were surveyed after discharge from hospital to determine their 
knowledge and understanding of newly-prescribed medication. Patients received either 
usual care (nurse counselling at discharge) or pharmacist counselling.  
 
The patients who received pharmacist counselling knew more about their new medicines.  
 
The study findings could help to more effectively target hospital pharmacist resource. 
Community pharmacist input was under-utilised and the study provides insights into the 
reasons for this. 
 
Abstract 
 
Aim 
To determine the effects of targeted hospital pharmacist counselling on discharge or 
targeted community pharmacy medicines reviews post-discharge on patients’ knowledge 
of newly started medication. 
Method 
Controlled trial of targeted medicines discharge counselling provided by hospital 
pharmacists or follow-up post-discharge medicines review provided by community 
pharmacists compared with usual care (nurse counselling). Outcomes measured using a 
 structured telephone survey conducted at two and four weeks after patients were 
discharged from hospital. 
Results 
Patients who received hospital pharmacist counselling were significantly more likely to 
report being told the purpose of their new medicine and how to take it than those receiving 
usual care. Fewer than half of the patients who were allocated to receive a community 
pharmacy medicines review did receive one. 
Conclusion 
The study results indicate that patient knowledge of medicines newly prescribed in hospital 
is increased by targeted counselling by hospital pharmacists. The findings also suggest 
the need to improve the consistency of the information covered when providing 
counselling, perhaps by the implementation of a counselling checklist for use by all 
disciplines of staff involved in patient counselling. The potential of community pharmacy 
follow-up medicines reviews is currently undermined by several barriers to uptake.   
 
Introduction 
Patients who are discharged from hospital often have new medicines prescribed and 
medicines-related problems at care transitions are a global problem for which solutions 
have long been sought. Discontinuity of care, multiple changes to medication either 
intentional or unintentional, and inadequate patient information can lead to adverse drug 
events. A systematic review of interventions to reduce medicines discontinuity at 
transitions found patient education and counseling at discharge and reinforced after 
discharge to be effective.1 However few studies linked hospital-based counselling with 
onward referral for community pharmacy based follow-up to support patients’ medicines 
use. Furthermore it may not be possible to provide pharmacist counselling in hospitals for 
all patients due to limitations on pharmacist resources and typically much counselling is 
provided by nurses. Little attention has been paid in previous research to how best to 
target pharmacist and nurse discharge medicines counselling. The current study set out to 
investigate the effects of targeted hospital pharmacist counselling and, where patients 
cannot be counselled by a hospital pharmacist on discharge, whether there might be a 
benefit in referral to their community pharmacist. In the UK community pharmacies in 
England are funded by the National Health Service to provide post-discharge medicines 
use reviews (MURs), thus offering the opportunity to study the effects of a more systematic 
linkage between hospital and handover to community. 
 
  
Aim 
To determine the effects of targeted hospital pharmacist counselling on discharge or 
targeted community pharmacy medicines reviews post-discharge on patients’ knowledge 
of newly started medication. 
 
 
Methods 
A telephone survey at 2 and 4 weeks following discharge was selected as the study 
method. A postal survey was considered but not chosen because of potentially lower 
response rates due to the requirement for completion on two occasions. The questions, 
which were piloted prior to the study, covered knowledge of: what the new medicine was 
for, how to take it, side-effects, tests and monitoring. Likert-type scales were used to 
assess patients’ knowledge of their new medicines. Open questions were included to 
enquire about patients’ opinions on the discharge medicines service provided and the 
information they had received. 
 
Patients from 11 medical wards in one NHS hospital in England who were discharged on 
one or more new medicines during a five month period in 2013 were invited to take part. 
Patients who did not manage their own medication or those who did not have capacity to 
provide informed consent were excluded. New medication was identified by ward 
pharmacists from prescriptions and medical notes or from the discharge letter (local policy 
required that changes to medication during admission should be documented in the 
discharge letter).  
 
Patients were allocated sequentially to one of four groups;  
1) Hospital pharmacist counselling 
2) Usual care (nurse or doctor counselling) + community pharmacy MUR 
3) Hospital pharmacist counselling + community pharmacy MUR  
4) Usual care 
 
Usual care: the hospital’s written policy on discharge medicines stated that the prescriber 
was responsible during the inpatient stay for communicating with the patient about any 
newly started, stopped or changed medication and ensuring medicines information needs 
were met, referring as necessary to a pharmacist. On discharge it was the nurse’s 
 responsibility to give the patient their copy of the discharge letter containing the list of 
discharge medicines, and to ensure the patient understood how to take their medicines 
and arrangements for obtaining a further supply. Pharmacy staff were responsible for 
counselling patients referred by their medical and nursing colleagues and patients 
identified during their stay as having specific counselling needs e.g. if the cause of their 
admission was related to poor adherence or they were prescribed certain ‘high risk’ 
medicines. 
 
Following granting of ethical and research governance approvals patients were 
approached by the lead researcher and given a participant information sheet with the 
details of the research together with a consent form and a MUR information leaflet 
explaining how their local community pharmacy could help after discharge. The documents 
were left with the patient for a minimum of 24 hours to enable the patient to read and ask 
questions prior to deciding whether to take part and, for those participating, to sign the 
consent form. The consent form requested permission to share discharge medicines 
information with the patient’s community pharmacy and GP (by providing them with a copy 
of the discharge letter). Patients who agreed to take part were asked for their contact 
details, including telephone number, and also whether they had a ‘regular’ community 
pharmacy. If they did, they were asked for the name and address of the pharmacy and that 
pharmacy was informed of the patients discharge and request for a MUR. If the patient 
was unable to provide details of a community pharmacy or the community pharmacy 
contacted was not accredited to carry out MURs they were allocated to groups 1 or 4.  
 
Participating patients were telephoned by the researcher approximately two weeks after 
discharge and asked to complete the survey. Patients allocated to groups 2 or 3 were also 
asked to arrange and attend a MUR at the community pharmacy which usually dispensed 
their prescriptions, and to give the researcher a suggested date for calling back for the 
follow-up survey. If they were unable to arrange a MUR or no longer wanted to have one 
they were reallocated to groups 1 or 4. Patients in groups 2 and 3 were contacted again to 
complete the telephone survey after their MUR. The actual follow-up period for completing 
the telephone survey was dependent on the group to which patients were allocated. 
Patients could ask to be called back at a more convenient time and some did so.  
 
The Fisher’s exact test was used to compare the hospital pharmacist intervention groups 
with usual care. This was an exploratory study and there was no information on which to 
 base an estimate of possible effect size, therefore a formal sample size calculation was 
not undertaken.  
 
 
Results and Discussion 
One hundred and one patients were recruited to the study and allocated sequentially to the 
four groups. The numbers in each group were not evenly distributed (Table 1) for the 
following reasons: i) hospital policy required patients newly prescribed high-risk medicines 
to be allocated to group 1 or 3; ii) the patient was unable to obtain a MUR (due to their not 
having a regular community pharmacy; their regular community pharmacy not being 
accredited to provide MURs; the patient being unable to travel to the pharmacy for an 
MUR; or at follow-up the patient no longer wanted to have a MUR) so were reallocated to 
groups 1 or 4. At follow-up, 18 patients were reallocated from groups 2 and 3. 
  
Eighty four patients (83.2% of those recruited) completed the study. Of the seventeen lost 
to follow-up; eight withdrew; four died; two had provided incorrect contact details; two were 
transferred to rehabilitation (not managing their own medicines); and one had their new 
medication stopped prior to discharge. 
 
Age, gender and number of new medicines were similar across the groups (Table 1).  
 
A total of 154 new medicines were prescribed.  Patients were able to recall the name of 
130 (84.4%) 95% CI [76.6%, 92.2%] of these and could state what 127 (82.5%) 95% CI 
[74.4%, 90.6%] were for.  
 
Due to the small number of patients completing the study in groups 2 and 3 (Table 1), and 
following statistical advice, data were combined for the hospital pharmacist counselling in 
groups 1 and 3 (A) and compared to standard discharge counselling by a healthcare 
professional and/or MUR in groups 2 and 4 (B) (Table 2). The four patient responses in 
group 3 after having a MUR were excluded due to the limitations of such a small sample 
size.  
 
Patients reported that 93.8% of medicines in group A were provided with an explanation of 
how to take them compared to 51.4% in group B (p<0.05). Similarly 82.5% of medicines in 
group A were provided with an explanation of their purpose compared to 52.7% in group B 
 (p<0.05). There was no statistically significant difference between groups A and B in the 
receipt of an explanation for how long it would take for the medication to act or what 
should be done if experiencing unwanted side-effects. A greater proportion of patients in 
group B compared to group A were not provided with information on how long they would 
need to be on the medication (77.0% vs. 52.5%) p= 0.001, tests or monitoring (68.9% vs. 
35.0%) p=0.000 or what to do if they forgot to take a dose (79.7% vs. 43.8%) p=0.000.  
After hospital pharmacist counselling only three patients stated they had not received as 
much information as they wanted compared with twelve patients in group B. 
 
Counselling patients in the intervention groups significantly improved patients’ knowledge 
of their medicines compared with usual care. Providing counselling has been shown to 
improve medication adherence and decrease readmission rates.2 The recall of information 
will vary and the possible effects of this on the study results is not known. Patients in 
groups 2 and 3 had to arrange a MUR with their community pharmacy and would state a 
period of time of when they would be able to visit their pharmacy and when it would be 
convenient for the researcher to call them back. This meant the period of time between the 
two telephone survey calls was longer. The information patients retain may also be linked 
to its perceived importance. In the study carried out by Berry et al, (1997)3 interactions with 
medication was ranked lower in importance by patients than by health professionals. This 
may partly explain the lower percentages of patients in both groups A and B agreeing 
(18.8% vs. 8.1%) when asked if an explanation was given about whether the medicine 
interferes with other medicines. 
 
The study had a number of limitations. The study hospital did not have a standard 
operating procedure (SOP) for specific medicines information items to be provided at 
discharge and it is therefore not possible to determine why items were omitted (possible 
reasons might be time constraints or that certain items are not usually covered by some 
staff). The results are also potentially limited by patient recall and the point of hospital 
discharge being a potentially stressful time when patients are waiting to be allowed to go 
home and therefore not ideal for information provision.  
 
The medicines counselling provided by staff prior to, or upon discharge was generally 
seen positively by patients. Cooper & Garrett (2014)4 studied inpatients’ experiences and 
preferences of receiving medicines information and education. In that study over one-third 
of patients indicated that they would have liked more time to talk about their medications 
 either in hospital or following discharge, of these 19% said they would have preferred a 
hospital pharmacist and 14% a community pharmacist. Some patients in the current study 
chose not to have a MUR with their community pharmacists but we do not know their 
reasons for this decision.  
 
A recent systematic review concluded that intervention by community pharmacists post 
discharge reduces medicines-related problems.5 Despite this potential post-discharge 
MURs were under-utilised in the current study, received by fewer than half of the patients 
for whom it was recommended in study group allocation. A common reason for this was 
that patients who had their medication delivered to their home and thus did not usually visit 
their community pharmacy could not be allocated to receive a MUR. The usual method of 
MUR delivery is face to face in the pharmacy with telephone delivery currently only 
possible if the community pharmacist requests prior permission on an individual patient 
basis. Possible strategies to address the study findings include providing telephone MURs 
to improve access, identifying patients’ MUR access and preferences while they are in 
hospital and targeting hospital pharmacist counselling more effectively, and providing 
feedback to service commissioners about how discharge medicines information services 
can be enhanced. An international review of regional and national initiatives relating to 
medicines at care transitions identified the importance of local implementation strategies in 
ensuring regional and national initiatives and policies work effectively.6 This study has 
provided insights into how local policies can be refined.     
 
 
Conclusion 
The results of this exploratory study indicate that patient knowledge of medicines newly 
prescribed in hospital is increased by targeted counselling by hospital pharmacists. The 
findings also suggest the need to improve the consistency of the information covered when 
providing counselling, perhaps by the implementation of a counselling checklist for use by 
all disciplines of staff involved in patient counselling. The potential of community pharmacy 
follow-up medicines reviews is currently undermined by several barriers including 
difficulties in access and patient reluctance to participate in a community pharmacy 
medicines review.   
 
Acknowledgements: 
 Doncaster & Bassetlaw Hospitals NHS Foundation Trust sponsored the MSc which 
allowed this study to be undertaken. Thanks are due to: Julie Kay for local clinical 
pharmacy advice and support and to the ward pharmacists who supported the study.  
 
References 
 
1. Spinewine A. Claeys C. Foulon V. & Chevalier P. Approaches for improving continuity of 
care in medication management: a systematic review. Int J Qual Health Care. 2013 
Sep;25(4):403-17. doi: 10.1093/intqhc/mzt032. Epub 2013 May 2. 
 
2. Vinluan C. Wittman D. & Morisky D. Effect of pharmacist discharge counselling on 
medication adherence in elderly heart failure patients: A pilot study. J Pharm Health Serv 
Res. 2015; 6(2): 103-110. 
 
3. Berry D. Michas I. Gillie T. & Forster M. What do patients want to know about their 
medicines, and what do doctors want to tell them?: A comparative study. Psychol. and 
Health 1997; 12: 467-480. 
 
4. Cooper J. & Garrett T. Providing medicines information and education to hospital in-
patients: Patients' experiences and preferences. J Pharm Pract and Res. 2014; 44(4): 213-
219.0 
 
5. Nazar H, Nazar Z, Portlock J, Todd A, Slight SP. A systematic review of the role of 
community pharmacies in improving the transition from secondary to primary care. Br J 
Clin Pharmacol. 2015 Nov;80(5):936-48. doi: 10.1111/bcp.12718. Epub 2015 Oct 3. 
 
6. Claeys C, Foulon V, de Winter S. & Spinewine A. Initiatives promoting seamless care in 
medication management: an international review of the grey literature. Int J Clin Pharm. 
2013 Dec;35(6):1040-52. 
 Table 1: Patient data 
 Group 1 Group 2 Group 3 Group 4 
Number of patients (initial group 
allocation) 
32 18 21 30 
Number of patients completing 
the study 
39 10 4 31 
Number of new medicines 76 23 4 51 
Average age (years) 68 67 45 64 
Number of male patients 21 3 3 13 
Number of female patients 18 7 1 18 
 
 Table 2: Comparison of patient responses (Groups A and B) 
Group 1 and 3 (A) patient responses for hospital pharmacist counselling (43 patient responses with 80 new medicines) compared to the group 2 and 4 (B) patient responses 
for standard discharge counselling by a healthcare professional and MUR community pharmacist counselling (41 patient responses with 74 new medicines) 
Did the pharmacist/ healthcare 
professional... 
Yes, definitely Yes, to some extent No I did not need an 
explanation 
Not applicable p value 
 Group A Group B Group A Group B Group A Group B Group A Group B Group A Group B  
…explain to you how to take the 
new medication(s)? 
75  
(93.8%) 
38 
(51.4%) 
1  
(1.2%)  
0 
(0.0%) 
4  
(5.0%) 
36 
(48.6%) 
0  
(0.0%) 
0 
(0.0%) 
- - 0.000 
…explain the purpose of the 
medication(s) you were to take 
home in a way you could 
understand? 
66  
(82.5%) 
39 
(52.7%) 
3  
(3.8%) 
2 
(2.7%) 
11  
(13.8%) 
33 
(44.6%) 
0  
(0.0%) 
0 
(0.0%) 
- - 0.000 
…explain the reason for the change 
to your medication in a way that you 
could understand? 
59  
(73.8%) 
38 
(51.4%) 
3  
(3.8%) 
0 
(0.0%) 
18  
(22.5%) 
36 
(48.6%) 
0  
(0.0%) 
0 
(0.0%) 
- - 0.001 
…explain how long you will need to 
be on your new medication? 
33  
(41.2%) 
11 
(14.9%) 
4  
(5.0%) 
6 
(8.1%) 
42  
(52.5%) 
57 
(77.0%) 
1  
(1.2%) 
0 
(0.0%) 
- - 0.001 
…explain about any tests or 
monitoring? 
32  
(40.0%) 
12 
(16.2%) 
9  
(11.2%) 
2 
(2.7%) 
28  
(35.0%) 
51 
(68.9%) 
0  
(0.0%) 
4 
(5.4%) 
11  
(13.8%) 
5 
(6.8%) 
0.000 
…explain how you can tell if your 
new medication is working? 
8  
(10.0%) 
13 
(17.6%) 
3  
(3.8%) 
0 
(0.0%) 
63  
(78.8%) 
61 
(82.4%) 
6  
(7.5%) 
0 
(0.0%) 
- - 0.011 
…explain how long it will take for 
your new medication to act? 
14  
(17.5%) 
8 
(10.8%) 
4  
(5.0%) 
4 
(5.4%) 
62  
(77.5%) 
62 
(83.8%) 
0  
(0.0%) 
0 
(0.0%) 
- - 0.508 
…tell you about medication side-
effects to watch for? 
27  
(33.8%) 
14 
(18.9%) 
2  
(2.5%) 
8 
(10.8%) 
51  
(63.8%) 
51 
(68.9%) 
0  
(0.0%) 
1 
(1.4%) 
- - 0.024 
…explain what you should do if you 
experience unwanted side-effects? 
34  
(42.5%) 
25 
(33.8%) 
1  
(1.2%) 
0 
(0.0%) 
45  
(56.2%) 
49 
(66.2%) 
0  
(0.0%) 
0 
(0.0%) 
- - 0.248 
…explain whether the medicine 
interferes with other medicines? 
15  
(18.8%) 
6 
(8.1%) 
2  
(2.5%) 
0 
(0.0%) 
42  
(52.5%) 
58 
(78.4%) 
0  
(0.0%) 
0 
(0.0%) 
21  
(26.2%) 
10 
(13.5%) 
0.005 
…explain what you should do if you 
forget to take a dose? 
42  
(52.5%) 
9 
(12.2%) 
0  
(0.0%) 
0 
(0.0%) 
35  
(43.8%) 
59 
(79.7%) 
3  
(3.8%) 
6 
(8.1%) 
- - 0.000 
Have you experienced any difficulty 
taking your new medication? 
3  
(3.8%) 
1 
(1.4%) 
1  
(1.2%) 
9 
(12.2%) 
76  
(95.0%) 
64 
(86.5%) 
0  
(0.0%) 
0 
(0.0%) 
- - 0.008 
 
 
 
